Philip Bonomi to ErbB Receptors
This is a "connection" page, showing publications Philip Bonomi has written about ErbB Receptors.
Connection Strength
2.985
-
Epidermal growth factor receptor pathway. J Thorac Oncol. 2010 Dec; 5(12 Suppl 6):S470-1.
Score: 0.375
-
Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Rev Anticancer Ther. 2010 Oct; 10(10):1589-99.
Score: 0.371
-
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J Clin Oncol. 2007 Sep 01; 25(25):3936-44.
Score: 0.300
-
Current strategies in the management of lung cancer. Oncology (Williston Park). 2005 Nov; 19(13):1667-8.
Score: 0.264
-
Epidermal growth factor receptor-targeted therapy and symptom improvement in non-small cell lung cancer. Am J Health Syst Pharm. 2003 Dec 15; 60(24 Suppl 9):S16-21.
Score: 0.232
-
Clinical studies with non-iressa EGFR tyrosine kinase inhibitors. Lung Cancer. 2003 Aug; 41 Suppl 1:S43-8.
Score: 0.226
-
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. Ann Oncol. 2018 08 01; 29(8):1701-1709.
Score: 0.160
-
Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells. Mol Cancer. 2013 Jul 16; 12:76.
Score: 0.113
-
Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Anticancer Res. 2012 May; 32(5):1705-10.
Score: 0.103
-
PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy. Br J Cancer. 2011 Dec 06; 105(12):1920-6.
Score: 0.100
-
Lung cancer: new developments point the way to reduced mortality. Oncology (Williston Park). 2011 Jan; 25(1):82, 84.
Score: 0.094
-
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res. 2008 Apr 01; 14(7):2088-94.
Score: 0.078
-
Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 2):s4606-12.
Score: 0.074
-
The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. J Thorac Oncol. 2007 May; 2(5):414-22.
Score: 0.073
-
Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol. 2006 Nov 20; 24(33):5253-8.
Score: 0.071
-
Therapeutic advances in second-line treatment of advanced non-small-cell lung cancer. Clin Lung Cancer. 2004 Nov; 6(3):154-61.
Score: 0.062
-
Locally advanced NSCLC: current state of the art, treatment and future directions. J Natl Compr Canc Netw. 2004 Sep; 2 Suppl 2:S23-30.
Score: 0.061
-
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol. 2004 Aug 15; 22(16):3238-47.
Score: 0.061
-
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol. 2019 02 01; 37(4):278-285.
Score: 0.041
-
The serum-based VeriStrat? test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer. 2018 03 20; 18(1):310.
Score: 0.039
-
Clinician Perspectives on Current Issues in Lung Cancer Drug Development. J Thorac Oncol. 2016 09; 11(9):1387-96.
Score: 0.035
-
Clinicopathologic Features of Advanced Squamous NSCLC. J Thorac Oncol. 2016 09; 11(9):1411-22.
Score: 0.034
-
Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. J Thorac Oncol. 2008 May; 3(5):545-55.
Score: 0.020